Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.30 | N/A | +17.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.30 | N/A | +17.09% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to ongoing pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. The positive EPS surprise indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 2, 2021